Value for companies advancing human healthcare. The advanced therapies and regenerative medicine technologies being developed today will transform medicine. The Adjuvant to make this happen. This is a partial list of our clients. It works, and is informed by experience.

Registration is open to credentialed investors and members of the media. Indicate your interest in attending today! Gain extensive exposure to the leading stakeholders field. For more info on available opportunities. Discounted rates are available now for conference attendees. Reserve your room at the Essex House today. 350 attendees including 175 active investors and analysts.

No double standards Advancements in cell and gene therapy. The Hospital for Sick Children is in the crosshairs of Catholic school trustees. Consider the value of implementation.

Dedicated to accelerating biotech innovation for rare disease treatments through science-driven public policy. We are a science-based advocacy organization that works to bring lifesaving treatments to the 30 million Americans with rare diseases. We focus on educating and activating the patient community to ensure they are heard by policy makers in government and by industry developing the treatments. Affecting 1 in 10 Americans. Have no FDA approved treatments. Sign Up for Our Newsletter.

Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.